Tregs and Rethinking Cancer Immunotherapy.
From: San Antonio Cancer Institute, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. curielt@uthscsa.edu
The Journal of clinical investigation
- Publish Date: May 2007
- ISSN: 0021-9738
- Volume: 117
- Issue: 5
- Pages: 1167-74
- Medium: Print
- Language: English
- Citation (JAMA): Curiel Tyler J, et al. Tregs and Rethinking Cancer Immunotherapy.. J. Clin. Invest. May 2007;117:1167-74
Abstract
Tumors express antigens that should induce immune-mediated rejection, but spontaneous rejection of established tumors is rare. Recent work demonstrates that one reason for the lack of tumor rejection is that tumors actively defeat host immunity. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. CD4+CD25+ Tregs are one mechanism of tumor-driven immune evasion that provide prototypical targets for testing novel anticancer treatment strategies within the newer paradigm.
Mesh Headings (Keywords): Animals, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Regulatory
Check for Full Text / PubMed Unique Identifier (PMID): 17476346
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.